By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
More parents refusing vitamin K shots for newborns, study finds - 2Pick Your Number one breakfast food
- 3New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- 4Kansas school officials report high student illness, dismiss early
- 5Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- The 10 Most Persuasive Forerunners in Innovation
- Vote in favor of your Number one Kind of Shades
- Find the Standards of Powerful Cooperation: Accomplishing Cooperative energy and Coordinated effort
- 10 Moves toward Start Your Own Effective Business
- The most effective method to Pick the Right Old Consideration Administration: Key Contemplations
- Putting pig organs in people is OK in the US, but growing human organs in pigs is not – why is that?
- The Response to Fake General Knowledge: Investigating the Eventual fate of artificial intelligence
